Current Setup & Catalysts

Current Setup & Catalysts — Molina Healthcare, Inc. (MOH)

The stock has retraced from the April 22, 2026 gap-down low at $129 back to $194.76 — within 4.6% of the pre-shock peak — without anybody declaring the FY2025 reset over. Consensus has marked the 2027 rebound at $8.07 of EPS against management's own disclosed walk to "approximately $7.50 of underlying" 2026 earnings before any rate restoration [1], which is the variant edge this page is built around. The next four prints decide whether the trough is real, and the July 22, 2026 Q2 print is the binary — the bull/bear gap is no longer the FY2026 mechanics, it is the slope from $5 into FY2027.

Last close (6/18/2026)

$194.76

Days to Q2 print (7/22)

Q2 consensus EPS ($)

$1.45

FY27 consensus EPS ($)

$8.07

FY26 consensus EPS ($)

$5.16

Sell-side mean PT ($)

$190.25

Ceiling tested 4x in June ($)

$205.00

Pre-shock support / invalidation ($)

$172.00

Setup read: Mixed, with binary skew into July 22. Recent prints, the legal market and S&P are short the credibility of management's framing; the procurement engine, the Burry disclosure and an internal Medicaid MCR snapshot at 92.0% in Q1 are long it. The Q2 print is the next forced choice. A clean miss reopens the litigation overhang and a $150-160 retest; a clean hold reopens the $215 case.

Where we are right now

Consensus has converged on management's own "at least $5" anchor for FY2026: the average FY26 EPS estimate is $5.16 across 18 analysts, with a 30-day revision split of 11 up / 1 down — i.e. the Street has been lifting the floor since Q1 cleared $2.35 against $1.91 consensus. FY2027 has revised up harder still — 8 up / 0 down in 30 days, from $5.77 ninety days ago to $8.07 today — but management is signaling a number well above that. CFO Mark Keim closed the April 23 call by flagging that the $2.50/share burden in 2026 (Florida CMS Kids implementation costs plus traditional MAPD product losses) is "certain to be positive impacts to our 2027 performance" [2], and CEO Joe Zubretsky used the Q4 FY2025 prepared remarks to disclose that the 2026 guidance "produces underlying earnings of approximately $7.50 per share" after adjusting for those same two items [1]. The market is paying for part of the $7.50 → $9+ path. It is not paying for the rate-catch-up call option on top of it.

Positioning and sentiment around that anchor are unusually split. The recommendation distribution is 1 strong buy / 3 buy / 13 hold / 0 sell / 1 strong sell at a mean target of $190.25 — i.e. essentially the spot price. The dispersion sits inside that mean: Mizuho stands at $215 / Outperform after a 6/8/2026 raise, Barclays sits at $199 / Underweight, and one outlier holds $129. Capital World, a top-20 holder, sold 1.66M shares on 6/8/2026; the same week, Michael Burry's MOH long was the lead headline on Yahoo Finance. Borrow and short-interest data are not staged for this run, so positioning cannot be quantified directly — but the legal market (a putative federal securities class action Hindlemann v. Molina Healthcare covering February 5 – July 23, 2025 [3]) and S&P's April 3, 2026 downgrade to BB- are the two visible, public expressions of "short the credibility."

The tape has read all of that and is sitting on it. The post-shock recovery from $129 to $200 has been textbook V-shape, but volume on the climb back from $170 has been conspicuously light (multiple sub-1M-share sessions through June) and the $204-205 ceiling has rejected the stock four times — March 31, June 9, June 10, June 16. A daily close above $205 reopens the $215+ path; a daily close below the pre-shock $172 support invalidates the recovery and re-engages the $130s scenario. Between those lines, the $500 million of remaining buyback authorization through December 31, 2026 [4] — about 13 days of 20%-participation ADV — is the marginal bid keeping the chart honest.

The variant view — sized in numbers, stated before the calendar

There are two places where the analyst sheet should differ from consensus heading into the July 22 print, and one place where the right call is to sit on consensus.

(1) FY2027 EPS — variant +18% to +30% vs Street. Consensus FY27E is $8.07. Management's own building blocks are: $5 FY26 floor + ~$1 MAPD exit drag that mechanically disappears + ~$1.50 Florida CMS Kids implementation-cost reversal at run-rate margin = ~$7.50 of underlying 2026 power [1], and both reversals are "certain" per the CFO [2]. On top of that, Zubretsky has quantified the rate-catch-up sensitivity: every 100 bps of Medicaid MCR is worth ~$5 per share [1]. The FY26 Medicaid MCR guide is 92.9% against a long-term target of 88-89% — a 300-400 bps gap. Even half-closing it adds ~$2-3 of FY27 EPS, putting the variant range at $9.50-10.50, or roughly +18% to +30% above the $8.07 print. The Street is partway up the bridge and not paying for the rate leg.

(2) Q2 FY2026 EPS — variant aligned at $1.40-1.60, but with asymmetric down skew. Consensus is $1.45 (high $2.04, low $0.98, 17 analysts) — a very wide range for a managed-care print, signaling that the buy side is divided on whether Q1's $2.35 was clean or whether the front-loaded earnings seasonality management called out [2] will fade harder in Q2 with Marketplace risk-adjustment payable accruals. Our view sits at the consensus midpoint, but the historical reaction pattern for negative surprises in this name (table below) is -17% to -22%, while reactions to in-line prints have been single-digit. The skew is the trade — even an in-line Q2 EPS that is paired with a downward "view" or a Marketplace payable build can re-rate the stock harder than the EPS number alone.

(3) FY2026 EPS — aligned with consensus at $5.16-5.25; no edge in the raise debate. Management has been explicit it will "not update guidance" at Investor Day or Q2 — Zubretsky said the call would only revisit the guide "after 2 full quarters of information" in Q3 [2]. Trading the Q2 print as a guidance raise is therefore a low-probability bet; the higher-probability bet is the FY2027 re-rate that follows the Q3 / Q4 prints.

The net variant view a PM should leave this page with: the right framing is "buy the Q2 print into a 100% rate-cycle option on FY2027," not "buy MOH on cyclical-trough." The stock is paying for the trough; it is not paying for the rate-restoration cycle the company itself has quantified.

Historical earnings price-reaction base rate

The single most important calibration for any high-impact catalyst here is how MOH has actually traded on the last eight prints. The pattern is binary and large.

No Results

The pattern is uncomfortable for sizing into July 22. The last four prints — including the Q1 FY2026 "beat" — have produced 1-day reactions of -22%, -19%, -18%, -20%. Even a clean EPS beat (Q1 2026 +23% surprise) printed -22% on the day because guidance was reaffirmed rather than raised. The average absolute 1-day move on the last eight prints is ~11.6%, against a managed-care peer-set baseline of 3-5%. The implication for July 22: even an in-line $1.45 EPS print, if paired with a Marketplace risk-adjustment build or a soft "view," can easily produce a -10% to -15% reaction. A clear beat with a tactical raise to the FY2026 floor is the only scenario that mechanically re-rates the stock — and management has pre-committed not to raise on July 22 [2].

What changed in the last 3-6 months

Since mid-March, three things have moved the underlying setup, and one thing has been priced in.

No Results

The two events that moved the long-term thesis are the Q4 FY2025 print (which retired the "13-15% long-term EPS growth" frame and introduced both the $5 floor and the 100 bps Medicaid MCR = ~$5/share sensitivity [1]) and the Q1 FY2026 Medicaid MCR of 92.0% — the first quarter inside the FY26 guide [5]. The S&P downgrade is priced into the cost of incremental capital but does not constrain near-term operations. The May 8 Investor Day is the under-the-radar event: management had committed on the Q1 call to publish "a detailed financial outlook for premium revenue and earnings per share through 2029" with the same "level of detail and specificity that has been our hallmark" [6], and public coverage of the event indicates no quantified 2029 EPS was disclosed. That is a new credibility item that has not yet been re-priced.

What the market is watching now

The live debate is narrow and unusually specific. There are exactly four contested items going into the Q2 print, and the same four items account for ~95% of the FY2027 EPS distribution.

No Results

Items 1, 2, and 3 are tested in the next two prints; item 4 plays out on the litigation calendar, not the earnings calendar.

Ranked catalyst timeline — by decision value, not by date

The catalyst list below is ranked by how much each event resolves the FY2027 EPS distribution, which is what the equity is now priced against. Three catalysts inside the next 6 months are genuinely decisive (rank 1, 2, 5); the others are setup-shaping but not stand-alone re-rating events. The Texas STAR/CHIP go-live (now scheduled for 2027 per the CFO on Q1 FY2026 [7]) and the Washington Apple Health 2028 RFP issuance live in the long-term thesis but sit at or beyond the 6-month window; both are included for completeness. Rank 4 — the Q4 FY2026 print and initial FY2027 guidance in February 2027 — is the single most thesis-resolving event in the 18-month frame but falls outside the 6-month catalyst window, so it is called out explicitly.

No Results

Which catalysts actually resolve the debate

Not every event in the table re-prices the equity. The matrix below separates the four catalysts that update durable thesis variables from those that merely add color.

No Results

Next 90 days — what to watch, in date order

Inside the next 90 days (June 19 – September 19, 2026), three items dominate. Everything else is set-up for them.

No Results

If the Q2 print on July 22 holds the $5 floor and Medicaid MCR comes in below 92.0%, the 30-day window through August carries the next set of catalysts — off-cycle rate disclosures and the Q2 13Fs — and the setup into the October print is for a test of the $204-205 ceiling. If Q2 brings a Marketplace payable build or a Medicaid MCR at/above 93.5%, the same 30-day window sets up an air-pocket retest toward $150-160.

What would change the view

Three observable signals over the next ~6 months would force a real underwriting change. None of them is an ordinary earnings beat or miss.

Medicaid MCR converges to 91% or below across two consecutive quarters. The single most powerful update to the long-term thesis. At management's disclosed sensitivity — every 100 bps of Medicaid MCR is worth ~$5/share [1] — a 180-200 bps move from the FY26 guide of 92.9% mechanically adds $9-10/share to FY27 power. This is the Pillar 1 confirmation, and it is the signal that re-rates the multiple from "trough P/E" toward through-cycle 14-16x. Inverse: Medicaid MCR at/above 93.5% across two prints invalidates the rate-cycle catch-up thesis and re-engages the "structural re-base" reading.
A second sequential guidance cut, or a second covenant amendment. A fourth cut would close the loop on the credibility narrative, re-engage the Hindlemann class action's central allegation, and almost certainly bring a follow-on S&P action — the FY2025 10-K's MCR sensitivity already quantifies how knife-edge the FY26 guide is: a one-percentage-point move on consolidated MCR cuts diluted EPS from $8.92 to $2.72 [8]. A second covenant amendment beyond the February 2026 cut from 3.00x to 1.75x interest coverage would be the lender writing in black ink that EBITDA-to-interest is tight. Either is a -25% event.
A Texas STAR/CHIP or Washington Apple Health 2028 procurement loss. The two largest binary outcomes inside the 5-year frame. The 10-K is explicit: "Incumbency status may not necessarily guarantee our ability to retain contracts when they are up for rebidding" [9]. Texas STAR/CHIP at roughly 18% of Medicaid revenue and Washington at ~13% (per the FY2025 10-K [10]) are 3-5x the dollar magnitude of the 2024 Virginia Cardinal Care loss. A loss in either would re-rate the franchise from "narrow-moat compounder" to "regulated yield substitute," irrespective of the next two earnings prints.

These are the three signals that force a thesis update. The Q2 print is not one of them by itself — a print is the trigger for information; the signals above are the trigger for a decision.

Bottom line. The recent setup is mixed-with-binary-skew into July 22. The variant view is +18-30% to consensus FY27 EPS based on management's own building blocks plus partial rate restoration. The catalyst path is unusually narrow and well-defined: three earnings prints and one procurement RFP over the next nine months resolve roughly 80% of the FY27 EPS distribution. Stay engaged in the $172-200 band, earn the position rather than chase it, and treat the Q3 FY2026 print as the FY27 re-rating trigger if the Q2 floor holds.

References

Generated Jun 19, 2026 10:03 UTC